$BIVI
BIOVIE INC. Stock $bivi

$bivi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000152013823000227 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.620M	$2.520M	$3.362M
YoY Change	-22.08%	19.2%	2762.77%
% of Gross Profit
Research & Development	$8.300M	$11.20M	$5.873M
YoY Change	41.33%	213.01%	-95.53%
% of Gross Profit
Depreciation & Amortization	$57.35K	$57.34K	$57.35K
YoY Change	0.0%	0.0%	-3.42%
% of Gross Profit
Operating Expenses	$10.98M	$13.77M	$9.292M
YoY Change	18.13%	139.61%	-92.94%
Operating Profit		-$13.77M
YoY Change		139.61%
Interest Expense	$1.865M	$1.083M	$1.203M
YoY Change	55.01%	-183.82%	15813.89%
% of Operating Profit
Other Income/Expense, Net		-$1.267M
YoY Change
Pretax Income	-$9.112M	-$15.04M	-$8.089M
YoY Change	12.65%	113.63%	-93.85%
Income Tax
% Of Pretax Income
Net Earnings	-$9.112M	-$15.04M	-$8.089M
YoY Change	12.65%	113.63%	-93.85%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.43
Diluted Earnings Per Share	-$0.25	-$0.43	-$323.8K
COMMON SHARES
Basic Shares Outstanding	36.28M shares	34.99M shares
Diluted Shares Outstanding		35.33M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.94M	$43.80M	$18.64M
YoY Change	82.06%	78.72%	313.19%
Cash & Equivalents	$19.46M	$31.28M	$18.64M
Short-Term Investments	$14.48M	$12.52M
Other Short-Term Assets	$102.5K	$249.8K	$137.9K
YoY Change	-25.64%	-12.35%	47.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$34.04M	$44.05M	$18.78M
YoY Change	81.27%	77.67%	307.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$80.79K	$90.55K	$118.3K
YoY Change	-31.68%	-28.76%
Goodwill	$345.7K	$345.7K	$345.7K
YoY Change	0.0%		0.0%
Intangibles	$637.1K	$694.4K	$866.5K
YoY Change	-26.47%		-20.93%
Long-Term Investments
YoY Change
Other Assets		$4.562K	$4.562K
YoY Change
Total Long-Term Assets	$1.064M	$1.135M	$1.335M
YoY Change	-20.33%	-18.71%	-7.39%
TOTAL ASSETS
Total Short-Term Assets	$34.04M	$44.05M	$18.78M
Total Long-Term Assets	$1.064M	$1.135M	$1.335M
Total Assets	$35.10M	$45.18M	$20.11M
YoY Change	74.52%	72.53%	232.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.476M	$4.839M	$2.443M
YoY Change	42.31%	301.15%	145.17%
Accrued Expenses	$44.91K	$43.31K	$38.88K
YoY Change	15.51%	48.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.105M	$6.391M
YoY Change
Total Short-Term Liabilities	$14.49M	$16.00M	$4.169M
YoY Change	247.66%	270.7%	318.44%
LONG-TERM LIABILITIES
Long-Term Debt	$5.227M	$7.406M	$12.14M
YoY Change	-56.94%	-36.3%
Other Long-Term Liabilities			$48.39K
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$48.39K
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.49M	$16.00M	$4.169M
Total Long-Term Liabilities	$0.00	$0.00	$48.39K
Total Liabilities	$19.76M	$23.46M	$16.44M
YoY Change	20.19%	44.54%	1550.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$301.2M	-$292.1M	-$251.0M
YoY Change	20.02%		11.6%
Common Stock	$316.4M	$313.8M	$254.6M
YoY Change	24.25%		10.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.00	$2.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.34M	$21.72M	$3.671M
YoY Change
Total Liabilities & Shareholders Equity	$35.10M	$45.18M	$20.11M
YoY Change	74.52%	72.53%	232.65%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q2
OPERATING ACTIVITIES
Net Income	-$9.112M	-$15.04M	-$8.089M
YoY Change	12.65%	113.63%	-93.85%
Depreciation, Depletion And Amortization	$57.35K	$57.34K	$57.35K
YoY Change	0.0%	0.0%	-3.42%
Cash From Operating Activities	-$11.29M	-$11.74M	-$5.865M
YoY Change	92.45%	99.42%	-16.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$1.796M	-$12.50M
YoY Change
Cash From Investing Activities	-$1.796M	-$12.50M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.268M	9.768M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-11.29M	-11.74M	-5.865M
Cash From Investing Activities	-1.796M	-12.50M
Cash From Financing Activities	1.268M	9.768M	0.000
Net Change In Cash	-11.82M	-14.47M	-5.865M
YoY Change	101.45%	145.93%	-14.32%
FREE CASH FLOW
Cash From Operating Activities	-$11.29M	-$11.74M	-$5.865M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001580149
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022Q2	bivi	Investments In U.S.Treasury Bills InvestmentsInU.s.TreasuryBills		usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue		usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
	bivi	Purchases Of U.S.Treasury Bills PurchasesOfU.s.TreasuryBills		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	bivi	Net Proceeds From Issuance Of Common Stock Related Party NetProceedsFromIssuanceOfCommonStockRelatedParty		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
	bivi	Unrealized Gain On U.S.Treasury Bill UnrealizedGainOnU.s.TreasuryBill		usd
CY2022Q4	bivi	Cashless Exercise Of Options CashlessExerciseOfOptions		usd
CY2022Q4	bivi	Cashless Exercise Of Warrants CashlessExerciseOfWarrants		usd
CY2023Q1	bivi	Issuance Of Restricted Stock Units IssuanceOfRestrictedStockUnits		usd
CY2022Q2	bivi	Current Portion Of Notes Payable CurrentPortionOfNotesPayable		usd
CY2022Q2	bivi	Debt Financing Costs DebtFinancingCosts		usd
CY2022Q2	us-gaap	Deferred Discounts Finance Charges And Interest Included In Receivables DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables		usd
CY2022Q2	bivi	Accretion Of Loan Premiums AccretionOfLoanPremiums		usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39015
	dei	Entity Registrant Name EntityRegistrantName	BIOVIE INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2510769
	dei	Entity Address Address Line1 EntityAddressAddressLine1	680 W Nye Lane Suite 204
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carson City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89703
	dei	City Area Code CityAreaCode	775
	dei	Local Phone Number LocalPhoneNumber	888-3162
	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	BIVI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36280541	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31276197	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18641716	usd
CY2023Q1	bivi	Investments In U.S.Treasury Bills InvestmentsInU.s.TreasuryBills	12521448	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	249790	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	137879	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	44047435	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	18779595	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	90549	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	118254	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	694439	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	866472	usd
CY2023Q1	us-gaap	Goodwill Goodwill	345711	usd
CY2022Q2	us-gaap	Goodwill Goodwill	345711	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4562	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4562	usd
CY2023Q1	us-gaap	Assets Assets	45182696	usd
CY2022Q2	us-gaap	Assets Assets	20114594	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4839209	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2442804	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	193542	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1304925	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	43314	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	38884	usd
CY2023Q1	bivi	Unearned Premium Anddiscount Current UnearnedPremiumAnddiscountCurrent	1108932	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	6391068	usd
CY2023Q1	bivi	Warrant Liabilities WarrantLiabilities	1956781	usd
CY2022Q2	bivi	Warrant Liabilities WarrantLiabilities	194531	usd
CY2023Q1	bivi	Embedded Derivative Liability EmbeddedDerivativeLiability	2580425	usd
CY2022Q2	bivi	Embedded Derivative Liability EmbeddedDerivativeLiability	188030	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16004339	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4169174	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48385	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	54465	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87414	usd
CY2023Q1	bivi	Unearned Premium And Discount UnearnedPremiumAndDiscount	94368	usd
CY2022Q2	bivi	Unearned Premium And Discount UnearnedPremiumAndDiscount	2861314	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	7405632	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	12138686	usd
CY2023Q1	us-gaap	Liabilities Liabilities	23464436	usd
CY2022Q2	us-gaap	Liabilities Liabilities	16443659	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36153911	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36131311	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24984083	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24984083	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	3613	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	2496	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	313811910	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	254638329	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	16505	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-292113766	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-250969890	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	21718260	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3670935	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45182696	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20114594	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	57344	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	57344	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172033	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172032	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11196835	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3577142	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24999665	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11385586	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2520330	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2114348	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8931957	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6403508	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	13774509	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	5748834	usd
	us-gaap	Operating Expenses OperatingExpenses	34103655	usd
	us-gaap	Operating Expenses OperatingExpenses	17961126	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13774509	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5748834	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34103655	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17961126	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-366093	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-386450	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-4154645	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	1168804	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1082762	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	918633	usd
	us-gaap	Interest Expense InterestExpense	3192631	usd
	us-gaap	Interest Expense InterestExpense	1236010	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	182201	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	13273	usd
	us-gaap	Interest Income Other InterestIncomeOther	307055	usd
	us-gaap	Interest Income Other InterestIncomeOther	32621	usd
CY2023Q1	bivi	Total Other Expense Income TotalOtherExpenseIncome	1266654	usd
CY2022Q1	bivi	Total Other Expense Income TotalOtherExpenseIncome	1291810	usd
	bivi	Total Other Expense Income TotalOtherExpenseIncome	7040221	usd
	bivi	Total Other Expense Income TotalOtherExpenseIncome	34585	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-15041163	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-7040644	usd
	us-gaap	Profit Loss ProfitLoss	-41143876	usd
	us-gaap	Profit Loss ProfitLoss	-17995711	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-15041163	usd
CY2022Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-7040644	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-41143876	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-17995711	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35325580	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24984083	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31217382	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24555382	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35325580	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24984083	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31217382	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24555382	shares
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15041163	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7040644	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41143876	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17995711	usd
CY2023Q1	bivi	Unrealized Gain On Investments For Availableforsale UnrealizedGainOnInvestmentsForAvailableforsale	16505	usd
	bivi	Unrealized Gain On Investments For Availableforsale UnrealizedGainOnInvestmentsForAvailableforsale	16505	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	16505	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	16505	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15024658	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7040644	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41127371	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17995711	usd
	us-gaap	Profit Loss ProfitLoss	-41143876	usd
	us-gaap	Profit Loss ProfitLoss	-17995711	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172033	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172032	usd
	bivi	Stock Based Compensation Restricted Stock StockBasedCompensationRestrictedStock	1589526	usd
	bivi	Stock Based Compensation Restricted Stock StockBasedCompensationRestrictedStock	384454	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3480425	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4004718	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	127664	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	56740	usd
	bivi	Interest Expense From Convertible Debenture InterestExpenseFromConvertibleDebenture	-1201083	usd
	bivi	Interest Expense From Convertible Debenture InterestExpenseFromConvertibleDebenture	-533815	usd
	bivi	Accretion Of Loan Premium AccretionOfLoanPremium	329267	usd
	bivi	Accretion Of Loan Premium AccretionOfLoanPremium	94444	usd
	bivi	Change In Operating Lease Rightofuse Assets ChangeInOperatingLeaseRightofuseAssets	27705	usd
	bivi	Change In Operating Lease Rightofuse Assets ChangeInOperatingLeaseRightofuseAssets	-77	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-4154645	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1168804	usd
CY2022Q3	bivi	Proceeds From Issuance Of Common Stock Net Of Costs Of94160 Related Party ProceedsFromIssuanceOfCommonStockNetOfCostsOf94160RelatedParty	5905840	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-10415711	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	5960923	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1554453	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1712787	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	111911	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	191480	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2396405	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	209949	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-28519	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1159768	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	774167	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28965321	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13125753	usd
	bivi	Purchases Of U.S.Treasury Bills PurchasesOfU.s.TreasuryBills	12504943	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12504943	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48196665	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18511009	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	14609915	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2240	usd
	bivi	Net Proceeds From Issuance Of Common Stock Related Party NetProceedsFromIssuanceOfCommonStockRelatedParty	5905840	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54104745	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33120924	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	12634481	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	19995171	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18641716	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4511642	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31276197	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24506813	usd
	us-gaap	Interest Paid Net InterestPaidNet	62693	usd
	us-gaap	Interest Paid Net InterestPaidNet	551011	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	130039	usd
	bivi	Unrealized Gain On U.S.Treasury Bill UnrealizedGainOnU.s.TreasuryBill	16505	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	5050315	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18511009	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	286759	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1926962	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5540753	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	20234292	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	97695	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1147422	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-5414317	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16065092	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	930334	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7040644	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	9954785	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3670935	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	878640	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	17537	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5903682	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2240	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	32524661	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-15687002	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26068062	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	17536	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	888998	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9768322	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-15041163	usd
CY2023Q1	bivi	Unrealized Gain On Availableforsale Securities UnrealizedGainOnAvailableforsaleSecurities	16505	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	21718260	usd
CY2023Q1	bivi	Working Capital WorkingCapital	28000000	usd
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	43800000	usd
CY2023Q1	bivi	Stockholder Equities StockholderEquities	21700000	usd
CY2023Q1	bivi	Accumulated Deficit AccumulatedDeficit	292000000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11741831	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2949507	shares
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2293770	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2293770	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1599331	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1427298	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	694439	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	866472	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	57344	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	57344	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172033	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172032	usd
CY2023Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	57344	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	229377	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	229377	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	178341	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	694439	usd
CY2023Q1	us-gaap	Other Liabilities OtherLiabilities	193542	usd
CY2022Q2	us-gaap	Other Liabilities OtherLiabilities	1300000	usd
CY2023Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	193542	usd
CY2022Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	580614	usd
CY2021Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1161000	usd
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.080	pure
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1400000	usd
	bivi	Fair Value Of Embedded Conversion Option FairValueOfEmbeddedConversionOption	2200000	usd
	bivi	Unearned Discount UnearnedDiscount	3700000	usd
	bivi	Direct Financing Cost DirectFinancingCost	390000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	850000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1100000	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	547000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	43000	usd
CY2023Q1	bivi	Unearned Discount UnearnedDiscount	400000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	3200000	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	1500000	usd
CY2023Q1	bivi	Accretions Of Loan Premium AccretionsOfLoanPremium	329000	usd
CY2022Q1	us-gaap	Notes Payable NotesPayable	11600000	usd
	bivi	Unearned Discount UnearnedDiscount	3100000	usd
CY2022Q1	bivi	Unamortized Direct Costs UnamortizedDirectCosts	333000	usd
CY2022Q1	bivi	Unamortized Accreted Premium UnamortizedAccretedPremium	94000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	919000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1200000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	43000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	57000	usd
CY2022Q1	bivi	Accretions Of Loan Premium AccretionsOfLoanPremium	71000	usd
	bivi	Accretions Of Loan Premium AccretionsOfLoanPremium	94000	usd
CY2023Q1	bivi	Current Portion Of Notes Payable CurrentPortionOfNotesPayable	7500000	usd
CY2023Q1	bivi	Debt Financing Costs DebtFinancingCosts	-134757	usd
CY2023Q1	us-gaap	Deferred Discounts Finance Charges And Interest Included In Receivables DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables	1267811	usd
CY2023Q1	bivi	Accretion Of Loan Premiums AccretionOfLoanPremiums	293636	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	6391068	usd
CY2023Q1	bivi	Notes Payable Noncurrent NotesPayableNoncurrent	7500000	usd
CY2022Q2	bivi	Notes Payable Noncurrent NotesPayableNoncurrent	15000000	usd
CY2023Q1	bivi	Longterm Debt Financing Costs LongtermDebtFinancingCosts	-28369	usd
CY2022Q2	bivi	Longterm Debt Financing Costs LongtermDebtFinancingCosts	-290790	usd
CY2023Q1	bivi	Long Term Deferred Discounts Finance Charges And Interest Included In Receivables LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables	-266908	usd
CY2022Q2	bivi	Long Term Deferred Discounts Finance Charges And Interest Included In Receivables LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables	-2735802	usd
CY2023Q1	bivi	Long Term Accretion Of Loan Premiums LongTermAccretionOfLoanPremiums	200909	usd
CY2022Q2	bivi	Long Term Accretion Of Loan Premiums LongTermAccretionOfLoanPremiums	165278	usd
CY2023Q1	bivi	Long Term Notes Payable Net Of Financing Costs Unearned Premiums And Discount LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount	7405632	usd
CY2022Q2	bivi	Long Term Notes Payable Net Of Financing Costs Unearned Premiums And Discount LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount	12138686	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	4537206	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	382561	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	43797645	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	18641716	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7952	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7512	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0361	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0160	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3443997	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1135948	shares
CY2022Q4	bivi	Total Compensation Cost TotalCompensationCost	1744192	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	13000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	23000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	36900	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	76500	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	90549	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	118254	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	43314	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	38884	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	54465	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87414	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	97779	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	126298	usd
	bivi	Schedule Of Future Estimated Minimum Lease Payments Under Non Cancelable Operating Leases ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases	<table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_z98Z9bQKXp1h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom"> <td> <span id="xdx_8B3_zi3puo7fCS4e" style="display: none">Schedule of future estimated minimum lease payments under non-cancelable operating leases</span></td><td> </td> <td colspan="2" id="xdx_49A_20230331_zaeDvXSRPJDb" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Year ending June 30, 2023 (Remaining 3 months)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,900</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,156</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: bottom; text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,636</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109,692</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayment_iNI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,913</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">97,779</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_z3rl9Ktxq4Q4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,314</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">54,465</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12900	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	52156	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	44636	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	109692	usd
CY2023Q1	bivi	Capital Leases Future Minimum Payments Interest Included In Payment CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayment	-11913	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	97779	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	43314	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	54465	usd
	bivi	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	12650	usd
	bivi	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	37700	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1075	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1075	pure
CY2023Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	16000	usd
CY2022Q1	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	28700	usd
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	80100	usd
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	75100	usd

Files In Submission

Name	View Source	Status
bivi-20230331_def.xml	Edgar Link	unprocessable
0001520138-23-000227-index-headers.html	Edgar Link	pending
0001520138-23-000227-index.html	Edgar Link	pending
0001520138-23-000227.txt	Edgar Link	pending
0001520138-23-000227-xbrl.zip	Edgar Link	pending
bivi-20230331.xsd	Edgar Link	pending
bivi-20230331_10q.htm	Edgar Link	pending
bivi-20230331_10qex31z1.htm	Edgar Link	pending
bivi-20230331_10qex31z2.htm	Edgar Link	pending
bivi-20230331_10qex32z1.htm	Edgar Link	pending
bivi-20230331_10qex32z2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
bivi-20230331_lab.xml	Edgar Link	unprocessable
bivi-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bivi-20230331_cal.xml	Edgar Link	unprocessable
bivi-20230331_10q_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIVI
BIOVIE INC. Stock $bivi

2023 Q2 Form 10-Q Financial Statement

#000152013823000227 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIVI BIOVIE INC. Stock $bivi

2023 Q2 Form 10-Q Financial Statement

#000152013823000227 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIVI
BIOVIE INC. Stock $bivi